Cindy H Chau
Overview
Explore the profile of Cindy H Chau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arisa O, Beatson E, Reno A, Chau C, Aurigemma R, Steeg P, et al.
Lancet Oncol
. 2024 Dec;
25(12):e685-e693.
PMID: 39637905
The translation of basic drug discoveries from laboratories to clinical use presents substantial challenges. Factors such as insufficient funding, misdirected project focus, and inability to understand a drug's limitations or...
2.
Orfanoudaki M, Dalilian M, Du L, Chau C, Figg W, OKeefe B, et al.
J Nat Prod
. 2024 Oct;
87(11):2640-2648.
PMID: 39453729
Chemical profiles of and were investigated, resulting in the isolation of five new discorhabdin D derivatives and -. Their planar structures were solved by combination of NMR and HR-MS, while...
3.
Barton B, Collins M, Chau C, Choo-Wosoba H, Venzon D, Steinebach C, et al.
Biomolecules
. 2024 Jun;
14(6).
PMID: 38927128
Immunomodulatory imide drugs (IMiDs) play a crucial role in the treatment landscape across various stages of multiple myeloma. Despite their evident efficacy, some patients may exhibit primary resistance to IMiD...
4.
Sievers J, Voget R, Lu F, Garchitorena K, Ng Y, Chau C, et al.
Bioorg Med Chem Lett
. 2024 Jun;
110:129858.
PMID: 38917956
Introduction of fluorine into bioactive molecules has attracted much attention in drug development. For example, tetrafluorination of the phthalimide moiety of immunomodulatory drugs (IMiDs) has a strong beneficial effect on...
5.
Beatson E, Risdon E, Napoli G, Price D, Chau C, Figg W
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892296
As we move into the era of precision medicine, the growing relevance of genetic alterations to prostate cancer (PCa) development and treatment demonstrates the importance of characterizing preclinical models at...
6.
Lee K, Beatson E, Knechel M, Sommer E, Napoli G, Risdon E, et al.
J Cancer
. 2024 Jan;
15(3):615-622.
PMID: 38213719
Extracellular vesicles (EVs) provide a minimally invasive liquid biopsy source of tumor-specific markers for patients who have already undergone prostatectomies. Our laboratory has previously demonstrated enrichment of the cancer-type solute...
7.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Dec;
30(3):907.
PMID: 38049623
No abstract available.
8.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Oct;
29(11):2737-2741.
PMID: 37865722
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and...
9.
Sun Y, Baechler S, Zhang X, Kumar S, Factor V, Arakawa Y, et al.
Nat Commun
. 2023 Jun;
14(1):3762.
PMID: 37353483
Colorectal cancers (CRCs) are prevalent worldwide, yet current treatments remain inadequate. Using chemical genetic screens, we identify that co-inhibition of topoisomerase I (TOP1) and NEDD8 is synergistically cytotoxic in human...
10.
Sommer E, Napoli G, Chau C, Price D, Figg W
iScience
. 2023 Mar;
26(3):106174.
PMID: 36895653
Identification of actionable drug targets remains a rate-limiting step of, and one of the most prominent barriers to successful drug development for metastatic cancers. CRISPR-Cas9, a tool for making targeted...